Anti-PDCD1 Recombinant Antibody (Nivolumab) (CAT#: TAB-770)

Recombinant human monoclonal antibody expressed in CHO binding to human PDCD1. Nivolumab is a fully human IgG4 monoclonal antibody for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.

Host: Human

Isotype: IgG4 - kappa

Applications: IF, IP, Neut, FuncS, ELISA, FC, ICC


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Limited PD-1 expression in normal human tissues.

Immunohistochemistry in positive control tissue, hyperplastic tonsil (A), using FITC-conjugated nivolumab. Strong immunoreactivity was distributed in subsets of lymphocytes primarily in germinal center of the tonsil; FITC-conjugated human IgG4 was used as an isotype control in tonsil (B). No specific staining was observed in cerebellum (C), heart (D), lung (E), or kidney (F). Positive staining was revealed in a very small number of scattered endocrine cells (G–I) in four of five pituitary samples. G and H represent two positive samples, and I represents negative pituitary tissue. Insets in G and H are high-power views showing strong immunoreactivity in large cytoplasmic spherical organelles, enigmatic body-like structures, with weak cytoplasmic staining. Br, bronchiole of the lung; GC, germinal center of the tonsil; Gl, glomerulus of the kidney; GL, granular layer of the cerebellum cortex; ML, molecular layer of the cerebellum cortex; MZ, mantle zone of the tonsil.

Wang, C., Thudium, K. B., Han, M., Wang, X. T., Huang, H., Feingersh, D., ... & Singh, S. (2014). In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer immunology research.

Figure 2 PD-1 blockade enhances T-cell function.

A, 105 purified CD4+ T cells were cocultured with 104 allogeneic monocyte-derived DCs in the presence of a titration of nivolumab or isotype control antibody in triplicates for 6 days. Supernatants were collected at day 5 and measured for IFNγ production by ELISA. The cultured cells were labeled with 1 μCi 3H-thymidine for another 18 hours before being analyzed for proliferation. Representative data from multiple donor DC/T-cell pairs are shown. CPM, counts per minute. B, 105 PBMCs were stimulated with serial dilutions of SEB in the presence of a fixed amount of nivolumab or isotype control antibody in solution (20 μg/mL). Supernatants were collected after 3 days for measurement of IL-2 by ELISA. Representative data from multiple healthy donors (n = 18) are shown. C, 2 × 105 PBMCs from a CMV-positive donor were stimulated with lysate from CMV-infected cells in the presence of nivolumab or isotype control. Supernatants were collected after 4 days and assayed for IFNγ secretion by ELISA. D, 5 × 104 CD4+CD25+ Tregs were cocultured with 105 CD4+CD25− responder T cells and 2 × 104 DCs in the presence of 20 μg/mL of nivolumab or isotype control antibody in an allogeneic MLR for 6 days. IFNγ was analyzed from the supernatants collected at day 5 and proliferation was measured at day 6 after 18 hours of 3H-thymidine labeling.

Wang, C., Thudium, K. B., Han, M., Wang, X. T., Huang, H., Feingersh, D., ... & Singh, S. (2014). In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer immunology research.

Figure 3 The absence of ADCC by nivolumab in vitro.

IL-2–activated human PBMCs (effector cells) were incubated with activated human CD4+ T cells (target cells) in an effector-to-target cell ratio of 50:1 in the presence of serial dilutions of nivolumab or a positive control anti-MHC class I antibody for 3 hour at 37°C. A–C, data from three individual ADCC assays using cells from different donors are shown. Purified CD4+ T cells were activated by coated anti-CD3 antibody (4 μg/mL) plus soluble anti-CD28 antibody (1 μg/mL) and IL-2 (100 U/mL) for 3 days. PD-1 expression on activated CD4+ T cells in each of the ADCC assays is shown in the right (solid line for PD-1, gray line for isotype control).

Wang, C., Thudium, K. B., Han, M., Wang, X. T., Huang, H., Feingersh, D., ... & Singh, S. (2014). In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer immunology research.

Figure 4 Pathological Assessment of Response to Neoadjuvant Blockade of Programmed Death 1 (PD-1).

Panel A shows pathological regression in the resected primary lung tumor after neoadjuvant administration of nivolumab, according to the percentage of remaining viable tumor cells, for each of the 20 patients who underwent surgical resection. The gray horizontal line indicates the threshold for a major pathological response (90% regression). Clinical and pathological features that include the presence or absence of lymph-node (LN) metastases in the surgical specimen and preoperative radiologic response (according to Response Evaluation Criteria in Solid Tumors [RECIST]) are annotated for each patient. AC denotes adenocarcinoma, SCC squamous-cell carcinoma, PR partial response, SD stable disease, and PD-L1 programmed death ligand 1. Also shown are biopsy specimens obtained before (Panel B) and after (Panel C) neoadjuvant administration of nivolumab in a patient (MD043-008) who had a major pathological response (multiplex immunofluorescence staining). With this staining technique, visible structures include cytokeratin-positive tumor cells (orange), CD68+ macrophages (magenta), FoxP3+ regulatory T cells (yellow), CD8+ T cells (green), PD-1+ cells (red), and PD-L1+ cells (white). In the pretreatment specimen, only a few intratumoral macrophages are seen expressing PD-L1. However, there are multiple foci where PD-L1 and PD-1 are expressed in close proximity to each other (inset with white circle) in the pretreatment specimen. Focal, geographic tumor-cell PD-L1 expression was observed in an adaptive pattern (not shown in this image). After two doses of nivolumab, the tumor is infiltrated by liquid containing CD8+ and PD-1+ immune cells. Some of the infiltrating immune cells express PD-L1, which is consistent with an adaptive immune resistance mechanism.

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., ... & Battafarano, R. J. (2018). Neoadjuvant PD-1 blockade in resectable lung cancer. New England Journal of Medicine, 378(21), 1976-1986.

Figure 5 Identification of Mutation-Associated, Neoantigen-Specific T Cells after Neoadjuvant Treatment with Nivolumab.

An antigen-recognition assay that evaluates in vitro expansion of T-cell clones after peptide stimulation was performed with the use of 47 algorithm-predicted, candidate mutation–associated neoantigens on peripheral-blood T cells obtained from Patient 1 before the administration of nivolumab (on day −28) and after administration (on day 44 after surgical resection) to determine the repertoire of functional mutation-associated neoantigen recognition. Seven mutation-associated neoantigens were recognized at both time points. The 47 peptides that were chosen for analysis represented the top 10 ImmunoSelect-R pipeline (Personal Genome Diagnostics) peptides that were predicted to bind specifically to each of the patient's five HLA class I alleles. Three peptides were excluded because they were predicted to bind multiple HLA alleles. Three T-cell clones from a peripheral-blood sample obtained on day 44 that specifically expanded in culture to mutation-associated neoantigen (MANA) number 7 were found in the pretreatment tumor-biopsy specimen and the resection specimen (Panel A). Also shown are the frequencies of the three T-cell clones in longitudinal analysis of peripheral-blood T cells before and after treatment (Panel B) and in a tumor-biopsy sample before treatment, in resected tumor, in normal lung, and in tumor-involved and tumor-uninvolved lymph nodes at resection (Panel C). TCR Vβ CDR3 AA denotes T-cell receptor Vβ complementarity-determining region 3 amino acid.

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., ... & Battafarano, R. J. (2018). Neoadjuvant PD-1 blockade in resectable lung cancer. New England Journal of Medicine, 378(21), 1976-1986.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG4 - kappa
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC
  • Trade name
  • opdivo
  • CAS
  • 946414-94-4
  • Generic Name
  • nivolumab
  • MW
  • 143.6 kDa
  • Related Disease
  • Cancers

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The PDCD1 antibody has been reported in applications of IHC, ELISA, ADCC, IF, Stim.
    ELISA: CD4+ T cells (1 × 105) and allogeneic DCs (1 × 104) were cocultured with or without dose titrations of nivolumab added at the initiation of the assay. After 5 days, IFNγ secretion in culture supernatants was analyzed by ELISA, and cells were labeled with 3H-thymidine for an additional 18 hours to measure T-cell proliferation.

Target

  • Alternative Names
  • nivolumab;opdivo;946414-94-4;ONO-4538;MDX-1106;BMS-936558;5C4;Opdivo;ONO-4538;BMS-936558;MDX1106;PDCD1;programmed cell death 1;programmed cell death protein 1;CD279;PD1;protein PD-1;PD-1;SLEB2;hPD-1;hPD-l;

Related Resources

  • Biosimilar Overview
Please refer to Nivolumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Nivolumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Nivolumab"

Afuco™ Anti-PDCD1 ADCC Recombinant Antibody (Nivolumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human PDCD1. Nivolumab is a fully human IgG4 monoclonal antibody for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.

See other products for "PDCD1"

Human Antibody

CAT Product Name Application Type
TAB-0961CL Anti-Human PDCD1 Recombinant Antibody (PD1-17) ELISA, FuncS Human antibody
TAB-0962CL Anti-Mouse Pdcd1 Recombinant Antibody (PD1-F2) ELISA Human antibody
TAB-0972CL-F(E) Human Anti-PDCD1 Recombinant Antibody; Fab Fragment (TAB-0972CL-F(E)) ELISA Human Fab
TAB-389CQ-S(P) Anti-Human PDCD1 Recombinant Antibody scFv Fragment (IBI308) ELISA Human antibody
TAB-389CQ-F(E) Anti-Human PDCD1 Recombinant Antibody Fab Fragment (IBI308) ELISA Human antibody

Humanized Antibody

CAT Product Name Application Type
TAB-0966CL Human Anti-PDCD1 Recombinant Antibody (TAB-0966CL) ELISA Humanized antibody
TAB-0975CL Human Anti-PDCD1 Recombinant Antibody (TAB-0975CL) ELISA Humanized antibody
TAB-0977CL Anti-Human PDCD1 Recombinant Antibody (949gH1a) FC Humanized antibody
TAB-0966CL-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0966CL-S(P)) ELISA Human scFv
TAB-0975CL-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0975CL-S(P)) ELISA Human scFv

Chimeric Antibody

CAT Product Name Application Type
TAB-0968CL Anti-Human PDCD1 Recombinant Antibody (cAB7) ELISA, WB Chimeric antibody (mouse/human)
TAB-0974CL Human Anti-PDCD1 Recombinant Antibody (TAB-0974CL) ELISA Chimeric (Mouse/Human) antibody
TAB-0968CL-S(P) Anti-Human PDCD1 Recombinant Antibody scFv Fragment (cAB7) ELISA, WB Chimeric antibody (mouse/human)
TAB-0974CL-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0974CL-S(P)) ELISA Human scFv
TAB-0974CL-F(E) Human Anti-PDCD1 Recombinant Antibody; Fab Fragment (TAB-0974CL-F(E)) ELISA Chimeric (Mouse/Human) Fab

Mouse Antibody

CAT Product Name Application Type
TAB-0978CL-S(P) Mouse Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0978CL-S(P)) ELISA Mouse scFv
TAB-0979CL-S(P) Mouse Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0979CL-S(P)) ELISA Mouse scFv
TAB-0980CL-S(P) Mouse Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0980CL-S(P)) ELISA Mouse scFv
TAB-0981CL-S(P) Mouse Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0981CL-S(P)) ELISA Mouse scFv
TAB-0963CL-F(E) Mouse Anti-PDCD1 Recombinant Antibody; Fab Fragment (TAB-0963CL-F(E)) FC Mouse Fab

Blocking Antibody

CAT Product Name Application Type
NEUT-1827CQ Recombinant Rat Anti-Pdcd1 Antibody (29F.1A12) BL, FC IgG2a
NEUT-1828CQ Recombinant Hamster Anti-Pdcd1 Antibody (J43) BL, WB IgG
NEUT-1829CQ Recombinant Rat Anti-Pdcd1 Antibody (RMP1-14) BL, WB IgG2a
NEUT-1830CQ Recombinant Rat Anti-Pdcd1 Antibody (HA2-7B1) BL IgG2b
NEUT-1831CQ Recombinant Hamster Anti-Pdcd1 Antibody (MAB0839) BL, FC IgG2

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1832CQ Recombinant Mouse Anti-PDCD1 Antibody (CBL151) Neut, WB IgG2
NEUT-1834CQ Recombinant Human Anti-PDCD1 Antibody (CBL1021) Neut IgG1, κ
NEUT-1835CQ Recombinant Mouse Anti-PDCD1 Antibody (9X21) Neut, WB IgG2

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-2622 Hi-Affi™ Recombinant Rabbit Anti-PDCD1 Monoclonal Antibody (DS2622AB) IHC IgG

Fab Fragment Antibody

CAT Product Name Application Type
HPAB-N0378-YC-F(E) Human Anti-PDCD1 Recombinant Antibody (clone 273_C12_C05); Fab Fragment FC, ELISA Human Fab
HPAB-0517LY-F(E) Human Anti-PDCD1 Recombinant Antibody (clone MIL75); Fab Fragment ELISA, Block Human Fab
HPAB-0518LY-F(E) Human Anti-PDCD1 Recombinant Antibody (clone CBL011LY); Fab Fragment ELISA, Block Human Fab
HPAB-0519LY-F(E) Mouse Anti-PDCD1 Recombinant Antibody (clone 1D2); Fab Fragment ELISA, Block Mouse Fab
HPAB-0520LY-F(E) Mouse Anti-PDCD1 Recombinant Antibody (clone 1G4); Fab Fragment ELISA, Block Mouse Fab

Recombinant Antibody

CAT Product Name Application Type
HPAB-0517LY Human Anti-PDCD1 Recombinant Antibody (clone MIL75) ELISA, Block Human IgG1
HPAB-0518LY Human Anti-PDCD1 Recombinant Antibody (clone CBL011LY) ELISA, Block Human IgG1
HPAB-0519LY Mouse Anti-PDCD1 Recombinant Antibody (clone 1D2) ELISA, Block Mouse IgG
HPAB-0520LY Mouse Anti-PDCD1 Recombinant Antibody (clone 1G4) ELISA, Block Mouse IgG
HPAB-0521LY Mouse Anti-PDCD1 Recombinant Antibody (clone 1H10) ELISA, Block Mouse IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-900 Afuco™ Anti-PDCD1 ADCC Recombinant Antibody (Pidilizumab), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA ADCC enhanced antibody
AFC-TAB-028ML Afuco™ Anti-PDCD1 ADCC Recombinant Antibody (Gilvetmab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-012ML Afuco™ Anti-PDCD1 ADCC Recombinant Antibody (Camrelizumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, BL ADCC enhanced antibody
AFC-TAB-770 Afuco™ Anti-PDCD1 ADCC Recombinant Antibody (Nivolumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-H55 Afuco™ Human Anti-PDCD1 Recombinant Antibody, ADCC Enhanced (AFC-TAB-H55) FuncS, IF, Neut, ELISA, FC IgG1, κ

Single-domain Antibody

CAT Product Name Application Type
HPAB-N0309-YC-VHH Recombinant Humanized Anti-PDCD1 Single Domain Antibody (NOV011YC) FC, ELISA Humanized VHH

scFv Fragment Antibody

CAT Product Name Application Type
HPAB-2975LY-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (HPAB-2975LY-S(P)) ELISA, WB, RIA Human scFv
HPAB-3043LY-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (HPAB-3043LY-S(P)) ELISA Human scFv
HPAB-1597-FY-F(E) Human Anti-PDCD1 Recombinant Antibody (clone 949); scFv Fragment Block Humanized scFv
HPAB-1598-FY-F(E) Mouse Anti-PDCD1 Recombinant Antibody (clone 948); scFv Fragment FC, ELISA Mouse scFv
HPAB-0481-YJ-S(P) Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (HPAB-0481-YJ-S(P)) ELISA, FC, Block, FuncS Human scFv

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-770. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

* Abbreviations
Send Inquiry
© 2023 Creative BioLabs. All Rights Reserved
  • 0
  • 0
Cart